Inactivated Vaccines Market Outlook 2025–2033
According to FutureWise analysis, the Inactivated Vaccines Market in 2025 is US$42.70 billion, and is expected to reach US$76.33 billion by 2033 at a CAGR of 7.53%.
Vaccines are biological preparations designed to create active acquired immunity to specific illnesses. Vaccinations are typically classified into four types: live-attenuated vaccines, toxoid vaccines, subunit vaccines, and inactivated vaccines. Inactivated vaccines are produced by inactivating a virus, bacterium, or pathogen using chemicals, such as formaldehyde, or through heat treatment. These pathogens are cultured in controlled environments and then destroyed to minimize their infectiousness. While inactivated vaccines can elicit an immune response, they are generally less effective than live-attenuated vaccines. To generate a sufficient immune response against illnesses, multiple booster doses and immunologic adjuvants are often necessary. Examples of inactivated vaccines include the seasonal influenza vaccine and the inactivated polio vaccine, both of which are included in the US Recommended Childhood Immunization Schedule. Because older vaccines tend to have lower immunogenicity, there is a high demand for newly developed vaccines with improved effectiveness. Researchers and industry stakeholders are investing in research and development to produce safe and effective vaccines, which is driving growth in the inactivated vaccines market. The introduction of new inactivated vaccines, following the completion of clinical trials, is expected to stimulate the market during the forecast period further. For instance, Merck's experimental inactivated varicella zoster virus vaccine (V212) has shown promise in reducing the incidence of herpes zoster in immunocompromised participants. Clinical trials indicate that V212 decreases the occurrence of herpes zoster pain by approximately 69.5% and also reduces the incidence of postherpetic neuralgia. Moreover, the rising prevalence of various viral and bacterial infections worldwide is increasing the demand for inactivated vaccines, which will contribute to market expansion.
FutureWise Market Research has instantiated a report that provides an intricate analysis of Inactivated Vaccines Market trends that shall affect the overall market growth.
Request a Free Sample @
https://www.futurewiseresearch.com/contact.aspx?rpt=14771&type=requestsample
By Type
- Viral vaccine
- Bacterial Vaccine
By Method
- Solvent Detergent Method
- Radiation Method
- pH Concentration
- Heat Inactivation
- Others
By Route of Administration
- Oral
- Subcutaneous
- Intravenous
- Others
By Region
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
Competitive Landscape in Inactivated Vaccines Market:
- Bharat Biotech
- CSL Ltd.
- Emergent BioSolutions
- GlaxoSmithKline plc
- MerckCo., Inc.
- Novartis AG
- Pfizer Inc.
- Sanofi
- Seqirus
- Valneva SE
Buy now the latest version of this report: https://www.futurewiseresearch.com/checkout.aspx?ReportId=14771&license=multi
**Objectives of this Study: **
- To provide a comprehensive analysis of the Inactivated Vaccines Market By Type, By Method, By Route of Administration and By Region.
- To offer detailed insights into factors such as drivers, restraints, trends, and opportunities, as well as segmental and regional influences on market growth.
- To evaluate current market trends and forecast micro-markets, presenting overall market projections in the form of data sets and PowerPoint presentations.
- To predict the market size in key regions, including North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.
Flexible Delivery Model:
- We have a flexible delivery model and you can suggest changes in the scope/table of contents as per your requirement
- The customization services offered are free of charge with the purchase of any license of the report.
- You can directly share your requirements/changes to the current table of contents to: [email protected]
